How should a patient with multiple episodes of anaphylaxis be managed to prevent future attacks?

Management of Recurrent Anaphylaxis

All patients with recurrent anaphylaxis must be prescribed two epinephrine auto-injectors, receive comprehensive education on trigger avoidance and device use, and be referred to an allergist for trigger identification and consideration of immunotherapy. 1

Immediate Post-Episode Management

After each anaphylactic episode, the following steps are essential:

• Prescribe two epinephrine auto-injectors at discharge—never just one, as patients need backup devices for home, school, or work 2
• Provide hands-on training on when and how to use the auto-injector correctly
• Educate patients on recognizing early signs and symptoms of anaphylaxis, including biphasic reactions that can occur hours after the initial episode 1
• Develop a written emergency action plan that patients can follow and share with caregivers 3

Dosing Considerations for Auto-Injectors

For children weighing less than 15 kg, either 0.1 mg or 0.15 mg epinephrine auto-injectors may be prescribed; for those weighing 25 kg or greater, use the 0.3 mg device 4. This represents updated guidance that allows for more individualized dosing in smaller children.

Trigger Identification and Avoidance

Referral to an allergist is mandatory, not optional 1, 5. The allergist will:

• Perform comprehensive diagnostic testing to confirm specific triggers (foods, medications, insect venoms, or other allergens)
• Measure serum tryptase levels to evaluate for underlying mast cell disorders, which are cofactors that increase anaphylaxis risk 6
• Assess for other cofactors that amplify reactions, such as exercise, NSAIDs, or alcohol 3
• Develop personalized avoidance strategies based on identified triggers

Notably, up to one-fifth of anaphylaxis cases have unidentified triggers 6, making specialist evaluation even more critical for developing appropriate management strategies.

Immunotherapy for Prevention

When appropriate triggers are identified, allergen immunotherapy can prevent future episodes and should be strongly considered 5:

• Venom immunotherapy for Hymenoptera (bee, wasp) hypersensitivity is highly effective at preventing recurrent reactions 7
• Aeroallergen immunotherapy may be appropriate for certain patients, though rush immunotherapy protocols should include premedication with glucocorticoids and/or antihistamines to reduce systemic reactions (RR 0.62; 95% CI 0.41-0.94) 1

This represents a disease-modifying intervention rather than just symptom management.

Risk Stratification

Certain patients face higher mortality risk and require intensified education and monitoring 6:

• Coexisting asthma (particularly poorly controlled)
• Underlying cardiovascular disease
• Older age
• Peanut and tree nut allergies
• Drug-induced reactions
• Underlying mast cell disorders

Important Caveat About Beta-Blockers and ACE Inhibitors

In patients with heart disease taking beta-blockers or ACE inhibitors, the risk of discontinuing these medications may outweigh the risk of severe anaphylaxis with medication continuation 4. This represents a shift from older recommendations that routinely advised stopping these medications. Shared decision-making with cardiology is essential.

Home Management Protocols

Recent guidelines acknowledge that activation of emergency medical services after home epinephrine administration may not be required in all cases 4, 8. Patients may manage at home when:

• Symptoms resolve promptly after epinephrine administration
• Caregivers are comfortable with observation
• There is adequate social support
• The patient has been educated on biphasic reactions

This requires shared decision-making between clinician and patient to determine appropriate home management protocols 8.

Common Pitfalls to Avoid

• Never delay epinephrine administration while considering antihistamines or corticosteroids—this is associated with higher morbidity and mortality 1
• Do not use epinephrine administration as a diagnostic criterion for anaphylaxis; diagnosis should be based on clinical criteria 8
• Routine corticosteroids are no longer recommended in updated guidelines 9
• Do not discharge patients without confirming they understand auto-injector technique—education must be hands-on, not just verbal 5
• Avoid prescribing only one auto-injector—patients need multiple devices in different locations 2

Long-Term Follow-Up Structure

Establish a systematic follow-up plan:

1. Allergist appointment within 1-2 weeks of the anaphylactic episode for diagnostic testing
2. Regular monitoring if immunotherapy is initiated
3. Annual review of emergency action plans and auto-injector prescriptions (which expire)
4. Reassessment of triggers and cofactors as clinical circumstances change

The evidence consistently demonstrates that specialist follow-up is essential for comprehensive risk assessment and prevention of future episodes 5, 3. Without allergist involvement, trigger identification remains incomplete and opportunities for disease-modifying interventions like immunotherapy are missed.